Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Annick de Bruin"'
Publikováno v:
Therapeutic Innovation & Regulatory Science
Background As clinical trial protocol designs become more complex and eligible patient populations narrow, it is becoming increasingly difficult to recruit participants and retain them for the duration of the trial. This study surveyed clinical trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9933e190b904aae4cc6168892d5b2339
https://doi.org/10.1007/s43441-021-00306-8
https://doi.org/10.1007/s43441-021-00306-8
Publikováno v:
Therapeutic Innovation & Regulatory Science. 54:1159-1165
Due to the extreme heterogeneity of lupus and the lack of consensus among stakeholders, pharmaceutical and biotechnology companies have had limited success in developing treatments for lupus. For this reason, the Lupus Foundation of America (LFA), re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c9a550cf3266b8103e89b45e70b56d5
https://doi.org/10.1007/s43441-020-00134-2
https://doi.org/10.1007/s43441-020-00134-2
Autor:
Kenneth A. Getz, Annick de Bruin
Publikováno v:
Drug Information Journal. 34:725-736
Reversing a 12-year trend, development cycle times have declined by 18% in the most recent three-year period. This paper explores the factors and company practices that are contributing to development speed. The authors analyzed 725 approved New Chem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0bdcccb59ea1070edcea04ca741271ae
https://doi.org/10.1177/009286150003400308
https://doi.org/10.1177/009286150003400308